Assisted with accounting and valuation for acquisition of Morphimmune
Assisted with accounting and valuation for acquisition of Morphimmune
In June 2023, Immunome entered a plan of merger with Morphimmune, Inc., a privately held biotechnology company.
Stout assisted with the technical accounting for the merger, prepared the combined pro forma financial information included in Immunome’s public filings with the SEC, and provided the valuation assistance for Morphimmune’s acquired compounds and other intellectual property.
